Picture of iBio logo

IBIO iBio Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Annual income statement for iBio, fiscal year end - June 30th, USD millions except per share, conversion factor applied.

2019
June 30th
C2020
June 30th
2021
June 30th
R2022
June 30th
2023
June 30th
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue2.021.642.371.880
Cost of Revenue
Gross Profit0.9350.909
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses17.815.633.531.629.3
Operating Profit-15.8-14-31.1-29.7-29.3
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-17.6-16.4-23.2-29.5-29.3
Net Income After Taxes-17.6-16.4-23.2-29.5-29.3
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income-17.6-16.4-23.2-50.3-65
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-17.9-38.3-23.5-50.4-65
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-472-305-60-63.8-47